Research
Hormonal
Tirzepatide produces superior weight loss and glycemic control compared to GLP-1 receptor agonists (e.g., semaglutide) by acting as a balanced dual GIP/GLP-1 receptor agonist, leveraging GIP-mediated effects on adipose tissue metabolism and insulin sensitivity.
Tirzepatide is a once-weekly injectable medication that targets both GLP-1 and GIP receptors. It has been shown to produce significant weight loss (up to 25% in some trials) and improve blood sugar control, often outperforming GLP-1-only drugs. It is prescribed for obesity and type 2 diabetes under medical supervision.
StrongSupportsVERY_HIGH confidence
Tirzepatide, a dual agonist of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors, has demonstrated remarkable effectiveness in lowering glucose levels and reducing weight in the SURPASS and SURMOUNT trials... tirzepatide (Zepbound)가 GLP-1수용체에만 특이적으로 작용하는 semaglutide 1.0 mg에 비해 체중감량의 정도가 우월한 결과를 보인 바 있다.
Why this rating
Supported by multiple high-impact clinical trials (SURPASS, SURMOUNT) and preclinical studies cited.
Source
GLP-1/GIP Receptor Agonists: Mechanism of Action of Tirzepatide
Tae Jung Oh · Journal of Korean Diabetes · 2024
narrative_reviewCited 2×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →